Resveratrol and Colorectal Cancer: A Molecular Approach to Clinical Researches

Curr Top Med Chem. 2021;21(29):2634-2646. doi: 10.2174/1568026621666211105093658.

Abstract

Phytochemicals are the most valuable and comprehensive structures, which may have a broad range of protective benefits, from reducing inflammation and speeding healing to preventing infection and fighting cancer. Resveratrol (RSV) is a natural phenolic compound from the oligomeric stilbenoids group, which is usually found in daily human diet, such as grape, peanut, berries and grains. It exhibits anti-inflammatory, neuroprotective, antioxidant, and cancer prevention and treatment effects. RSV is thought to have an impressive outcome in colorectal cancer (CRC) treatment through the vital molecules and cancer signaling pathways, including SIRT1, P53, P21, AMPK, ROS, BMP7, COX-2, NO, caspases, Wnt, TNFs, NF-κB, EMT, and pentose phosphate pathway. Therefore, this paper reviews the current researches on the pharmacological effects and pharmacokinetics of resveratrol and its drug delivery system, as well as clinical studies involving CRC.

Keywords: Clinical study.; Colorectal cancer; Pharmacokinetic; Pharmacology; Phenolic compound; Resveratrol; Stilbenoid.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Antioxidants
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / metabolism
  • Drug Delivery Systems
  • Humans
  • Neuroprotective Agents
  • Resveratrol* / administration & dosage
  • Resveratrol* / pharmacokinetics
  • Resveratrol* / pharmacology
  • Resveratrol* / therapeutic use
  • Signal Transduction / drug effects

Substances

  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Antioxidants
  • Neuroprotective Agents
  • Resveratrol